Mavoglurant Effective Against Cocaine Addiction in Phase 2 Trial
The drug company, Novartis, reports a significant decline in cocaine use with mavoglurant in phase 2 trial.
The Endocannabinoid System and Addiction
New research looks at developing endocannabinoid receptor agonists for the treatment of obesity, PTSD and drug addiction.